Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
Status:
RECRUITING
Trial end date:
2029-09-11
Target enrollment:
Participant gender:
Summary
This is a single-arm, prospective clinical study to evaluate the efficacy and safety of orelabrutinib combined with rituximab as first-line systemic treatment for marginal zone lymphoma.
Phase:
PHASE2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators:
Affiliated Hospital of Jiaxing University Dongyang People's Hospital Huzhou Central Hospital Ningbo People's Hospital Second Affiliated Hospital of Wenzhou Medical University Shaoxing Central Hospital Shaoxing People's Hospital Taizhou Central Hospital affiliated to Taizhou University Taizhou First People's Hospital Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University The Central Hospital of Lishui City The People's Hospital of Quzhou The Second Affiliated Hospital of Jiaxing University Yuyao People's Hospital Zhejiang Cancer Hospital Zhejiang University Zhuji People's hospital